Impact of airflow limitation in chronic heart failure
Impact of airflow limitation in chronic heart failure
复制标题
DOI：
10.1007/s12471-017-0965-4
复制
发表时间：
2017-05-01
影响因子：
2
通讯作者：
Brunner-La Rocca, H. P.
中科院分区：
文献类型：
--
作者：
Bektas, S.;Franssen, F. M. E.;Brunner-La Rocca, H. P.
背景慢性心力衰竭（HF）患者中合并症很常见，但诊断通常不是基于客观检测。慢性阻塞性肺疾病（COPD）是一种重要的合并症，由于共同的症状和危险因素而经常被忽视。确切的流行程度和后果尚不清楚。因此，我们调查的患病率，肺部治疗，症状和COPD的生活质量（QOL）在慢性HF.Methods 205例稳定HF至少1个月，年龄在50岁以上，包括从我们的心脏病门诊，无论左心室射血分数。患者进行支气管扩张剂后肺量测定、6分钟步行试验（6-MWT），并完成堪萨斯城心肌病问卷（KCCQ）。根据GOLD标准诊断COPD。限制性肺功能定义为FEV 1/FVC >= 0.70和FVC
Background Comorbidities are common in chronic heart failure (HF) patients, but diagnoses are often not based on objective testing. Chronic obstructive pulmonary disease (COPD) is an important comorbidity and often neglected because of shared symptoms and risk factors. Precise prevalence and consequences are not well known. Therefore, we investigated prevalence, pulmonary treatment, symptoms and quality of life (QOL) of COPD in patients with chronic HF.Methods 205 patients with stable HF for at least 1 month, aged above 50 years, were included from our outpatient cardiology clinic, irrespective of left ventricular ejection fraction. Patients performed post-bronchodilator spirometry, a six-minute walk test (6-MWT) and completed the Kansas City Cardiomyopathy Questionnaire (KCCQ). COPD was diagnosed according to GOLD criteria. Restrictive lung function was defined as FEV1/FVC >= 0.70 and FVC